Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists. (February 2020)

• Record Type: Journal Article
• Authors: Sellers, Rani S.; Nelson, Keith; Bennet, Bindu; Wolf, Jayanthi; Tripathi, Niraj; Chamanza, Ronnie; Perron Lepage, Marie-France; Adkins, Karissa; Laurent, Sebastien; Troth, Sean P.
• Is Part Of: Toxicologic pathology. Volume 48:Number 2(2020)
• Page Start: 257
• Page End: 276
• Publication Date: 2020-02
• Subjects: vaccine -- regulatory toxicology -- species selection -- injection site -- adjuvant -- vaccine study design; Pathology -- Periodicals; Toxicology -- Periodicals; Pathology; Toxicology; 615.9
• DOI: 10.1177/0192623319875085
• Languages: English
• ISSNs: 0192-6233

Abstract

The design and execution of toxicology studies supporting vaccine development have some unique considerations relative to those supporting traditional small molecules and biologics. A working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee conducted a review of the scientific, technical, and regulatory considerations for veterinary pathologists and toxicologists related to the design and evaluation of regulatory toxicology studies supporting vaccine clinical trials. Much of the information in this document focuses on the development of prophylactic vaccines for infectious agents. Many of these considerations also apply to therapeutic vaccine development (such as vaccines directed against cancer epitopes); important differences will be identified in various sections as appropriate. The topics addressed in this Points to Consider article include regulatory guidelines for nonclinical vaccine studies, study design (including species selection), technical considerations in dosing and injection site collection, study end point evaluation, and data interpretation. The intent of this publication is to share learnings related to nonclinical studies to support vaccine development to help others as they move into this therapeutic area. *This Points to Consider article is a product of a Society of Toxicologic Pathology (STP) Working Group commissioned by the Scientific and Regulatory Policy Committee (SRPC) of the STP. It has been reviewed and approved by the SRPC and Executive Committee of the STP but does not represent a formal best practice recommendation. The views expressed in this article are those of the authors and do not necessarily represent the policies, positions, or opinions of their respective agencies and organizations. Readers of Toxicologic Pathology are encouraged to send their thoughts on these articles or ideas for new topics to the editor.